二甲双胍治疗2型糖尿病与亚临床甲状腺功能减退症关系的研究

摘要

目的：：观察临床应用二甲双胍治疗2型糖尿病与亚临床甲状腺功能减退症的关系。方法：选取2013年6月至2014年7月在我院诊治的124例2型糖尿病患者，按随机数字表法随机分为对照组和观察组各62例，对照组患者给予拜糖苹口服治疗，观察组则应用二甲双胍治疗，观察两组患者治疗后亚临床甲状腺功能减退症的发生情况。结果：实验室检查表明，观察组患者的 TSH 及 HOMA－IR均明显低于对照组( P<0.05)，其他各项指标比较无明显差异( P>0.05)，应用二甲双胍是减少甲状腺功能减退症发生的保护因素，性别是其危险因素。结论：临床应用二甲双胍治疗2型糖尿病能减少甲状腺功能减退症的发生率，值得推广应用。%Objective:To explore the relationship between metformin in treating II diabetes mellitus and subclinical hypothyroidism. Methods: 124 cases with II diabetes mellitus treated in our hospital from June 2013 to July 2014 were selected and divided into two groups randomly, the control group and the observation group, each group with 62 cases. The control group was treated with bayer pharma, and the observation group was treated with metformin. The subclinical hypothyroidism of two groups was observed after treatment. Re-sults:The experimental results indicated that TSH and HOMA-IR of the observation group was evidently lower than that of the control group ( P<0.05) , and the other indicators had no evident difference( P>0.05) . Apply-ing metformin was a protective factor of reducing subclinical hypothyroidism, and sex is an dangerous factor. Conclusion:Applying metformin to treat II diabetes mellitus can reduce the incidence rate of subclinical hy-pothyroidism, which is worthy of promotion and application.